Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Multigen + cholecystokinin is not a recognized fixed-dose combination or co-packaged pharmaceutical product. **Multigen** is a brand name for a prescription hematinic supplement typically containing ferrous fumarate (iron), cyanocobalamin (vitamin B12), and folic acid, indicated for the treatment of iron-deficiency anemias and associated nutritional deficiencies. **Cholecystokinin** (CCK) is a gastrointestinal peptide hormone that stimulates gallbladder contraction and pancreatic enzyme secretion. In clinical practice, synthetic analogs of CCK, such as sincalide (Kinevac), are used as diagnostic agents to evaluate gallbladder and pancreatic function during imaging procedures like hepatobiliary (HIDA) scans. There is no established therapeutic or diagnostic rationale for combining a daily oral iron supplement with an injectable gastrointestinal hormone into a single drug product, and no such product is verified in clinical pipelines or regulatory databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Multigen + cholecystokinin.